Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1207 vs Eylea in treatment-naïve neovascular age-related macular degeneration (Phase III, randomized double-blind active-controlled)
CTR20190937Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QL1207 in exudative macular degeneration, sponsored by Qilu Pharmaceutical. Started May 2019; status: completed.
02
Drugs
QL1207
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20190937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190937.